Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

27 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Indirect Ophthalmoscopy Screening Ranibizumab Macular Edema Diabetes Mellitus FVF4170g - Indirect Ophthalmoscopy Screening

- 21/03/18 - 1 modulo, 4 itemgroups, 48 elementi, 1 linguaggio
Itemgroups: Indirect Ophthalmoscopy Right Eye, Indirect Ophthalmoscopy Left Eye , Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Screening. A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus.

Indirect Ophthalmoscopy Screening Ranibizumab Macular Edema Diabetes Mellitus FVF4168g - Indirect Ophthalmoscopy Screening

- 21/03/18 - 1 modulo, 4 itemgroups, 48 elementi, 1 linguaggio
Itemgroups: Indirect Ophthalmoscopy Right Eye, Indirect Ophthalmoscopy Left Eye , Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Screening. A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus.

Indirect Ophthalmoscopy Screening Ranibizumab Macular Edema Secondary To Branch Retinal Vein Occlusion FVF4165g - Indirect Ophthalmoscopy Screening

- 18/03/18 - 1 modulo, 4 itemgroups, 52 elementi, 1 linguaggio
Itemgroups: Indirect Ophthalmoscopy Right Eye, Indirect Ophthalmoscopy Left Eye , Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Screening. A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection Compared With Sham In Subjects with Macular Edema Secondary To Branch Retinal Vein Occlusion.

Indirect Ophthalmoscopy Screening Ranibizumab Age-Related Macular Degeneration FVF3192g - Indirect Ophthalmoscopy Screening

- 22/02/18 - 1 modulo, 4 itemgroups, 22 elementi, 1 linguaggio
Itemgroups: Indirect Ophthalmoscopy Right Eye, Indirect Ophthalmoscopy Left Eye , Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Screening. A Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study Of The Efficacy And Safety Of Ranibizumab In Subjects With Subfoveal Choroidal Neovascular (CNV) With Or Without Classic CNV Secondary To Age-Related Macular Degeneration.

Indirect Ophthalmoscopy Month 3 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2598g - Indirect Ophthalmoscopy Month 3

- 18/02/18 - 1 modulo, 3 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Indirect Ophthalmoscopy Right Eye, Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Month 3. A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) In Subjects With Minimally Classic Or Occult Subfoveal Neovascular Age-Related Macular Degeneration.

Indirect Ophthalmoscopy Day 0 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2598g - Indirect Ophthalmoscopy Day 0

- 18/02/18 - 1 modulo, 3 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Indirect Ophthalmoscopy Right Eye, Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Day 0. A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) In Subjects With Minimally Classic Or Occult Subfoveal Neovascular Age-Related Macular Degeneration.

Indirect Ophthalmoscopy Screening rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2598g - Indirect Ophthalmoscopy Screening

- 18/02/18 - 1 modulo, 4 itemgroups, 22 elementi, 1 linguaggio
Itemgroups: Indirect Ophthalmoscopy Right Eye, Indirect Ophthalmoscopy Left Eye , Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Screening. A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) In Subjects With Minimally Classic Or Occult Subfoveal Neovascular Age-Related Macular Degeneration.

Indirect Ophthalmoscopy Month 12 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Indirect Ophthalmoscopy Month 12

- 04/02/18 - 1 modulo, 3 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Indirect Ophthalmoscopy Right Eye, Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Month 12. A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

Indirect Ophthalmoscopy Month 11 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Indirect Ophthalmoscopy Month 11

- 24/01/18 - 1 modulo, 3 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Indirect Ophthalmoscopy Right Eye, Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Month 11. A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

Indirect Ophthalmoscopy Month 10 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Indirect Ophthalmoscopy Month 10

- 24/01/18 - 1 modulo, 3 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Indirect Ophthalmoscopy Right Eye, Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Month 10. A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

Indirect Ophthalmoscopy Month 9 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Indirect Ophthalmoscopy Month 9

- 24/01/18 - 1 modulo, 3 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Indirect Ophthalmoscopy Right Eye, Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Month 9. A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

Indirect Ophthalmoscopy Month 8 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Indirect Ophthalmoscopy Month 8

- 23/01/18 - 1 modulo, 3 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Indirect Ophthalmoscopy Right Eye, Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Month 8. A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial